Sarah Voytek, PhD

Biography

Sarah Voytek is a drug developer with more than 15 years of experience working in preclinical and translational development at biotech and large pharma companies in Boston. She obtained her PhD from The Scripps Research Institute, where she researched in vitro evolution of catalytic RNAs, and her BS from Brown University.
Sarah started her career at Novartis, working in Discovery and Investigative Safety, where she led a laboratory studying pharmacologic & toxicologic drug mechanisms and served as a preclinical safety lead. Later at bluebird bio, Sarah oversaw translational development spanning discovery through marketing approval for multiple gene therapy products.
Most recently, Sarah has worked at early-stage companies to drive the development of new therapeutic modalities. At Abata Therapeutics, she led the development of Treg cell therapy products for autoimmune diseases. Currently, Sarah is Vice President of Translational Medicine, and Global Program Lead at nChroma Bio, where she is developing an epigenetic medicine for chronic hepatitis B.